New insider activity at Abbott Laboratories ( (ABT) ) has taken place on March 8, 2025.
Lisa Earnhardt, EVP and Group President of Abbott Laboratories, has recently sold 91,367 shares of the company’s stock, amounting to a significant transaction worth $12,227,295.
Recent Updates on ABT stock
Abbott Laboratories has seen recent developments that have influenced its stock price targets. A collaboration agreement with Cadrenal Therapeutics to support a pivotal clinical trial has been announced, which could potentially enhance Abbott’s position in the healthcare sector. Additionally, Citi raised Abbott’s price target due to the company’s strong Q4 performance and momentum, although they also noted potential litigation risks that could affect future stock movements. Other analysts have similarly raised their price targets, reflecting confidence in Abbott’s growth prospects despite existing challenges.
More about Abbott Laboratories
YTD Price Performance: 20.05%
Average Trading Volume: 6,214,126
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $238.8B